ヒスチジン銅注射液の安定性およびヒスタミン含有量の検討

Translated title of the contribution: Stability of Copper Histidinate Injection and Histamine Formation in Menkes Disease

Youichi Kawasaki, 徳永 紳, 松香 直行, 出石 通博, 横山 紀子, 川島 理恵子, 亀井 千晃, Toshiaki Sendou, 五味田 裕

Research output: Contribution to journalArticle

Abstract

Menkes disease is characterized by inhibition of the absorption and transport of dietary copper. The Okayama University Medical and Dental School uses L-histidine-copper to treat this disease and in the present study, we examined the stability of the copper histidinate injection solution used for this purpose. High-performance liquid chromatography (HPLC) performed on day 56 following injection revealed that histidine levels had dropped to 90.4%, a non-significant decrease and histamine levels were unchanged. Moreover, atomic absorption spectrophotometry revealed that copper concentrations were not significantly decreased (89.7%) between days 0 and 56. Through visual observation, we noted a gradual increase in floats from day 42 to day 56, leading us to suggest that the use of copper histidinate be limited to 1 month. The above results should alleviate any concern about histamine-associated adverse effects.
Original languageJapanese
Pages (from-to)1133-1137
Number of pages5
Journal医療薬学
Volume32
Issue number11
DOIs
Publication statusPublished - Nov 10 2006

Fingerprint

Menkes Kinky Hair Syndrome
Histamine
Copper
Injections
Histidine
Atomic Spectrophotometry
Dental Schools
Medical Schools
High Pressure Liquid Chromatography
Observation

Keywords

  • copper histidinate
  • Menkes disease
  • histamine
  • high performance liquid chromatography
  • atomic absorption spectrophotometer
  • stability

Cite this

Kawasaki, Y., 徳永紳, 松香直行, 出石通博, 横山紀子, 川島理恵子, ... 五味田裕 (2006). ヒスチジン銅注射液の安定性およびヒスタミン含有量の検討. 医療薬学, 32(11), 1133-1137. https://doi.org/10.5649/jjphcs.32.1133

ヒスチジン銅注射液の安定性およびヒスタミン含有量の検討. / Kawasaki, Youichi; 徳永紳; 松香直行; 出石通博; 横山紀子; 川島理恵子; 亀井千晃; Sendou, Toshiaki; 五味田裕.

In: 医療薬学, Vol. 32, No. 11, 10.11.2006, p. 1133-1137.

Research output: Contribution to journalArticle

Kawasaki, Y, 徳永紳, 松香直行, 出石通博, 横山紀子, 川島理恵子, 亀井千晃, Sendou, T & 五味田裕 2006, 'ヒスチジン銅注射液の安定性およびヒスタミン含有量の検討', 医療薬学, vol. 32, no. 11, pp. 1133-1137. https://doi.org/10.5649/jjphcs.32.1133
Kawasaki Y, 徳永紳, 松香直行, 出石通博, 横山紀子, 川島理恵子 et al. ヒスチジン銅注射液の安定性およびヒスタミン含有量の検討. 医療薬学. 2006 Nov 10;32(11):1133-1137. https://doi.org/10.5649/jjphcs.32.1133
Kawasaki, Youichi ; 徳永紳 ; 松香直行 ; 出石通博 ; 横山紀子 ; 川島理恵子 ; 亀井千晃 ; Sendou, Toshiaki ; 五味田裕. / ヒスチジン銅注射液の安定性およびヒスタミン含有量の検討. In: 医療薬学. 2006 ; Vol. 32, No. 11. pp. 1133-1137.
@article{a1d0e5c263b942b6bef802bb69700a53,
title = "ヒスチジン銅注射液の安定性およびヒスタミン含有量の検討",
abstract = "Menkes disease is characterized by inhibition of the absorption and transport of dietary copper. The Okayama University Medical and Dental School uses L-histidine-copper to treat this disease and in the present study, we examined the stability of the copper histidinate injection solution used for this purpose. High-performance liquid chromatography (HPLC) performed on day 56 following injection revealed that histidine levels had dropped to 90.4{\%}, a non-significant decrease and histamine levels were unchanged. Moreover, atomic absorption spectrophotometry revealed that copper concentrations were not significantly decreased (89.7{\%}) between days 0 and 56. Through visual observation, we noted a gradual increase in floats from day 42 to day 56, leading us to suggest that the use of copper histidinate be limited to 1 month. The above results should alleviate any concern about histamine-associated adverse effects.",
keywords = "copper histidinate, Menkes disease, histamine, high performance liquid chromatography, atomic absorption spectrophotometer, stability",
author = "Youichi Kawasaki and 紳 徳永 and 直行 松香 and 通博 出石 and 紀子 横山 and 理恵子 川島 and 千晃 亀井 and Toshiaki Sendou and 裕 五味田",
year = "2006",
month = "11",
day = "10",
doi = "10.5649/jjphcs.32.1133",
language = "Japanese",
volume = "32",
pages = "1133--1137",
journal = "医療薬学",
publisher = "日本医療薬学会",
number = "11",

}

TY - JOUR

T1 - ヒスチジン銅注射液の安定性およびヒスタミン含有量の検討

AU - Kawasaki, Youichi

AU - 徳永, 紳

AU - 松香, 直行

AU - 出石, 通博

AU - 横山, 紀子

AU - 川島, 理恵子

AU - 亀井, 千晃

AU - Sendou, Toshiaki

AU - 五味田, 裕

PY - 2006/11/10

Y1 - 2006/11/10

N2 - Menkes disease is characterized by inhibition of the absorption and transport of dietary copper. The Okayama University Medical and Dental School uses L-histidine-copper to treat this disease and in the present study, we examined the stability of the copper histidinate injection solution used for this purpose. High-performance liquid chromatography (HPLC) performed on day 56 following injection revealed that histidine levels had dropped to 90.4%, a non-significant decrease and histamine levels were unchanged. Moreover, atomic absorption spectrophotometry revealed that copper concentrations were not significantly decreased (89.7%) between days 0 and 56. Through visual observation, we noted a gradual increase in floats from day 42 to day 56, leading us to suggest that the use of copper histidinate be limited to 1 month. The above results should alleviate any concern about histamine-associated adverse effects.

AB - Menkes disease is characterized by inhibition of the absorption and transport of dietary copper. The Okayama University Medical and Dental School uses L-histidine-copper to treat this disease and in the present study, we examined the stability of the copper histidinate injection solution used for this purpose. High-performance liquid chromatography (HPLC) performed on day 56 following injection revealed that histidine levels had dropped to 90.4%, a non-significant decrease and histamine levels were unchanged. Moreover, atomic absorption spectrophotometry revealed that copper concentrations were not significantly decreased (89.7%) between days 0 and 56. Through visual observation, we noted a gradual increase in floats from day 42 to day 56, leading us to suggest that the use of copper histidinate be limited to 1 month. The above results should alleviate any concern about histamine-associated adverse effects.

KW - copper histidinate

KW - Menkes disease

KW - histamine

KW - high performance liquid chromatography

KW - atomic absorption spectrophotometer

KW - stability

U2 - 10.5649/jjphcs.32.1133

DO - 10.5649/jjphcs.32.1133

M3 - Article

VL - 32

SP - 1133

EP - 1137

JO - 医療薬学

JF - 医療薬学

IS - 11

ER -